Literature DB >> 12657136

Changes in retinoblastoma gene expression during cervical cancer progression.

Mauricio Salcedo1, Lucía Taja, Dolores Utrera, Pedro Chávez, Alfredo Hidalgo, Carlos Pérez, Luis Benítez, Cristina Castañeda, Ricardo Delgado, Patricio Gariglio.   

Abstract

The role of tumour suppressor genes in the development of human cancers has been studied extensively. In viral carcinogenesis, the inactivation of suppressor proteins such as retinoblastoma (pRb) and p53, and cellular oncogenes overexpression, such as c-myc, has been the subject of a number of investigations. In uterine-cervix carcinomas, where high-risk human papillomavirus (HPV) plays an important role, pRb and p53 are inactivated by E7 and E6 viral oncoproteins, respectively. However, little is known about the in situ expression of some of these proteins in pre-malignant and malignant cervical tissues. On the other hand, it has also been demonstrated that c-myc is involved in cervical carcinogenesis, and that pRb participates in the control of c-myc gene expression. By using immunostaining techniques, we investigated pRb immunodetection pattern in normal tissues, squamous intraepithelial lesions (SILs) and invasive carcinomas from the uterine cervix. Our data show low pRb detection in both normal cervical tissue and invasive lesions, but a higher expression in SILs. C-Myc protein was observed in most of the cellular nuclei of the invasive lesions, while in SILs was low. These findings indicate a heterogeneous pRb immunostaining during the different stages of cervical carcinogenesis, and suggest that this staining pattern could be a common feature implicated in the pathogenesis of uterine-cervix carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12657136      PMCID: PMC2517690          DOI: 10.1046/j.1365-2613.2002.00198.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  52 in total

1.  Altered expression of the retinoblastoma gene product in human sarcomas.

Authors:  W G Cance; M F Brennan; M E Dudas; C M Huang; C Cordon-Cardo
Journal:  N Engl J Med       Date:  1990-11-22       Impact factor: 91.245

2.  The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines.

Authors:  M Scheffner; K Münger; J C Byrne; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

Review 3.  Role of the retinoblastoma gene in the initiation and progression of human cancer.

Authors:  W F Benedict; H J Xu; S X Hu; R Takahashi
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

4.  C-terminal truncation of the retinoblastoma gene product leads to functional inactivation.

Authors:  J Y Shew; B T Lin; P L Chen; B Y Tseng; T L Yang-Feng; W H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1990-01       Impact factor: 11.205

5.  The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product.

Authors:  N Dyson; P M Howley; K Münger; E Harlow
Journal:  Science       Date:  1989-02-17       Impact factor: 47.728

6.  Occurrence of human papillomavirus type 16 DNA sequences and c-myc oncogene alterations in uterine-cervix carcinoma.

Authors:  R Ocádiz; R Sauceda; M Salcedo; V Ortega; H Rodríguez; C Gordillo; P Chávez; P Gariglio
Journal:  Arch Invest Med (Mex)       Date:  1989 Oct-Dec

7.  Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells.

Authors:  J M Horowitz; S H Park; E Bogenmann; J C Cheng; D W Yandell; F J Kaye; J D Minna; T P Dryja; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

8.  The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours.

Authors:  J M Varley; J Armour; J E Swallow; A J Jeffreys; B A Ponder; A T'Ang; Y K Fung; W J Brammar; R A Walker
Journal:  Oncogene       Date:  1989-06       Impact factor: 9.867

9.  Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas.

Authors:  H J Xu; S X Hu; P T Cagle; G E Moore; W F Benedict
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

10.  Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers.

Authors:  H Yoshikawa; T Kawana; K Kitagawa; M Mizuno; H Yoshikura; A Iwamoto
Journal:  Jpn J Cancer Res       Date:  1991-05
View more
  4 in total

Review 1.  Aberrant cell cycle regulation in cervical carcinoma.

Authors:  Young Tae Kim; Min Zhao
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

2.  miR-23b as a potential tumor suppressor and its regulation by DNA methylation in cervical cancer.

Authors:  Gabriela Elizabeth Campos-Viguri; Hilda Jiménez-Wences; Oscar Peralta-Zaragoza; Gricenda Torres-Altamirano; Diana Guillermina Soto-Flores; Daniel Hernández-Sotelo; Luz Del Carmen Alarcón-Romero; Marco Antonio Jiménez-López; Berenice Illades-Aguiar; Gloria Fernández-Tilapa
Journal:  Infect Agent Cancer       Date:  2015-11-30       Impact factor: 2.965

3.  Loss of robustness and addiction to IGF1 during early keratinocyte transformation by human Papilloma virus 16.

Authors:  Tamar Geiger; Alexander Levitzki
Journal:  PLoS One       Date:  2007-07-11       Impact factor: 3.240

4.  Functional regulatory role of STAT3 in HPV16-mediated cervical carcinogenesis.

Authors:  Shirish Shukla; Sutapa Mahata; Gauri Shishodia; Arvind Pandey; Abhishek Tyagi; Kanchan Vishnoi; Seemi F Basir; Bhudev C Das; Alok C Bharti
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.